Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHA:688016)

China · Delayed Price · Currency is CNY

85.48

+1.64 (1.96%)

Sep 30, 2026, 3:00 PM CST

Market Cap	10.33B -21.2%
Revenue (ttm)	1.43B +26.2%
Net Income	571.04M +38.2%
EPS	4.77 +42.3%
Shares Out	120.84M
PE Ratio	17.94
Forward PE	16.42
Dividend	2.30 (2.69%)
Ex-Dividend Date	Jun 5, 2026

Volume	1,095,496
Open	83.85
Previous Close	83.84
Day's Range	83.60 - 85.75
52-Week Range	82.36 - 116.00
Beta	0.05
Analysts	Buy
Price Target	127.25 (+48.87%)
Earnings Date	Oct 30, 2026

About SHA:688016

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low ... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2012

Employees 859

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688016

Full Company Profile

Financial Performance

In 2025, SHA:688016's revenue was 1.35 billion, an increase of 11.96% compared to the previous year's 1.21 billion. Earnings were 563.33 million, an increase of 12.19%.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for 688016 stock is "Buy." The 12-month stock price target is ¥127.25, which is an increase of 48.87% from the latest price.

Price Target

¥127.25

(48.87% upside)

Analyst Consensus: Buy

Stock Forecasts